Cargando…

Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites

OBJECTIVE: IL-6 and catecholamines play roles in the pathophysiology of major depressive disorder (MDD). AIM: The present study investigated associations between plasma IL-6 and plasma catecholamine metabolites in patients with MDD. PARTICIPANTS AND METHODS: A total of 148 patients (male/female 65/8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshimura, Reiji, Kishi, Taro, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752655/ https://www.ncbi.nlm.nih.gov/pubmed/31686824 http://dx.doi.org/10.2147/NDT.S195379

Ejemplares similares

Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study
por: Yoshimura, Reiji, et al.
Publicado: (2018)

Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses
por: Kishi, Taro, et al.
Publicado: (2018)

Associations between plasma levels of C-reactive protein and catecholamine metabolites in patients with major depression
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Voxel-based morphometric brain comparison between healthy subjects and major depressive disorder patients in Japanese with the s/s genotype of 5-HTTLPR
por: Igata, Natsuki, et al.
Publicado: (2017)

Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
por: Kishi, Taro, et al.
Publicado: (2020)

Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients
por: Yoshimura, Reiji, et al.
Publicado: (2014)

A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder
por: Katsuki, Asuka, et al.
Publicado: (2019)

Genetic effects on white matter integrity in drug-naive patients with major depressive disorder: a diffusion tensor imaging study of 17 genetic loci associated with depressive symptoms
por: Kakeda, Shingo, et al.
Publicado: (2019)

No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients
por: Yoshimura, Reiji, et al.
Publicado: (2012)

Volume of Amygdala Subregions and Plasma Levels of Brain-Derived Neurotrophic Factor and Cortisol in Patients with s/s Genotype of Serotonin Transporter Gene Polymorphism of First-Episode and Drug-Naive Major Depressive Disorder: An Exploratory Study
por: Okamoto, Naomichi, et al.
Publicado: (2022)

Influence of antidepressants on plasma levels of nitric oxide metabolites in patients with major depressive disorder
por: Ikenouchi, Atsuko, et al.
Publicado: (2021)

Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study
por: Okamoto, Naomichi, et al.
Publicado: (2020)

COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder
por: Otsuka, Yuka, et al.
Publicado: (2019)

Influence of antidepressants on plasma levels of nitric oxide metabolites in patients with major depressive disorder – RETRACTION
por: Ikenouchi, Atsuko, et al.
Publicado: (2022)

Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study
por: Ueda, Issei, et al.
Publicado: (2016)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura, Reiji, et al.
Publicado: (2017)

Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression
por: Yoshimura, Reiji, et al.
Publicado: (2022)

No Elevated Plasma Catecholamine Levels during Sleep in Newly Diagnosed, Untreated Hypertensives
por: Rasch, Björn, et al.
Publicado: (2011)

Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression
por: Kishi, Taro, et al.
Publicado: (2022)

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2019)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao, Kei, et al.
Publicado: (2013)

Relationship between interleukin (IL)-6 and brain morphology in drug-naïve, first-episode major depressive disorder using surface-based morphometry
por: Kakeda, Shingo, et al.
Publicado: (2018)

COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study
por: Hayashi, Kenji, et al.
Publicado: (2014)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
por: Kishi, Taro, et al.
Publicado: (2019)

A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
por: Kishi, Taro, et al.
Publicado: (2023)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs
por: Yoshimura, Reiji, et al.
Publicado: (2014)

Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2016)

Probiotics Affect One‐Carbon Metabolites and Catecholamines in a Genetic Rat Model of Depression
por: Tillmann, Sandra, et al.
Publicado: (2018)

Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Plasma metabolites were associated with spatial working memory in major depressive disorder
por: Du, Yue, et al.
Publicado: (2021)

Effects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism
por: Sieber-Ruckstuhl, Nadja, et al.
Publicado: (2017)

Current Sample Preparation Methodologies for Determination of Catecholamines and Their Metabolites
por: Shi, Nian, et al.
Publicado: (2022)

Regional increases of cortical thickness in untreated, first-episode major depressive disorder
por: Qiu, L, et al.
Publicado: (2014)

Major depression with musical obsession treated with vortioxetine: a case report
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder
por: Atake, Kiyokazu, et al.
Publicado: (2015)

Differential genetic correlations across major psychiatric disorders between Eastern and Western countries
por: Saito, Takeo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ulb5i06u3q4aqmfp348607u8l2